|
Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol , No 18S ( Supplement), :
© 2008 American Society of Clinical Oncology
| Post-Progression Rx Type |
Record Review N=355
|
Record Review and Interview N=126
|
|
| No chemotherapy |
239 |
67.3% |
70 |
55.6% |
| Any chemotherapy agent |
116 |
32.7% |
56 |
44.4% |
| Type of chemotherapy: |
|
|
|
|
| Any gemcitabine |
49 |
13.8% |
25 |
19.8% |
| Any bevacizumab |
5 |
1.4% |
3 |
2.4% |
| Any intravenous 5FU |
40 |
11.3% |
22 |
17.5% |
| Any capecitabine |
34 |
9.6% |
18 |
14.3% |
| Other approved drug |
62 |
17.5% |
27 |
21.4% |
| Any experimental therapeutic drug |
5 |
1.4% |
2 |
1.6% |
|
|
